Proximal subtotal pancreatectomy as an alternative to total pancreatectomy for malnourished patients

Nakagawa, Yuki; Kato, Hiroyuki; Maeda, Koki; Noguchi, Daisuke; Gyoten, Kazuyuki; Hayasaki, Aoi; Iizawa, Yusuke; Fujii, Takehiro; Tanemura, Akihiro; Murata, Yasuhiro; Kuriyama, Naohisa; Kishiwada, Masashi; Sakurai, Hiroyuki; Isaji, Shuji; Mizuno, Shugo

doi:10.1007/s00595-021-02269-7

Cited by 3 publications

(1 citation statement)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Wittingen et al 23 evaluated the relative concentrations in various parts of the pancreas and had shown that the islet concentration of the tail is significantly greater than the concentration in the head and body. Moreover, Nakagawa et al 24 suggested how important it is to preserve as much of the pancreatic tail as possible to control blood glucose level after pancreatectomy. Thus, these reports are consistent with the data obtained from the present study.…”

Section: Discussionmentioning

confidence: 99%

Clinical outcomes of organ‐preserving pancreatectomy for benign or low‐grade malignant pancreatic tumors: A multicenter nationwide survey in Japan

Asano

Kato

Arakawa

et al. 2022

J Hepato Biliary Pancreat

Self Cite

View full text Add to dashboard Cite

Background/Purpose Whether organ‐preserving pancreatic surgery has an advantage in postoperative short‐ and long‐term outcomes or not is still unknown because only small case series studies have been available to date. In this multicenter retrospective study, we aimed to elucidate the clinical advantage and disadvantage of organ‐preserving pancreatectomy among patients with low‐grade malignant pancreatic tumors and benign pancreatic diseases. Methods We included patients diagnosed with benign or low‐malignant pancreatic tumor who underwent pancreaticoduodenectomy (PD) in 621 cases, duodenum‐preserving pancreatic head resection (DPPHR) in 31 cases, middle pancreatectomy (MP) in 148 cases, distal pancreatectomy (DP) in 814 cases, and spleen‐preserving distal pancreatectomy (SPDP) in 259 cases between January 1, 2013, and December 31, 2017. Preoperative backgrounds, surgical outcomes and pre‐ and postoperative (3, 6, 12, 24, and 36 months) nutritional status were compared between these procedures. Results In terms of short‐term outcomes, the incidence of pancreatic fistula in patients who underwent MP was significantly higher than in patients with standard pancreatectomy. As for the long‐term pancreatic functions in the cases of head or body lesion, both exocrine and endocrine functions after MP were significantly favorable compared with the PD group from 3 to 36 months after surgery. In pancreatic body or tail lesion, significant advantage of endocrine function, but not exocrine function, was found in the MP group compared to standard DP at all time points. Conclusions MP may contribute to the improvement of postoperative quality of life for patients with pancreatic body low‐malignant tumors, rather than PD or DP; however, reducing the incidence of short‐term complications such as pancreatic fistula is a future challenge.

show abstract

Section: Discussionmentioning

confidence: 99%

Clinical outcomes of organ‐preserving pancreatectomy for benign or low‐grade malignant pancreatic tumors: A multicenter nationwide survey in Japan

Asano

Kato

Arakawa

et al. 2022

J Hepato Biliary Pancreat

Self Cite

View full text Add to dashboard Cite

show abstract

Low incidence of pancreatic fistula and well‐preserved endocrine function with non‐reconstructed small remnant pancreas after pancreaticoduodenectomy

Miyashita,

Yoshioka,

Fukumura

et al. 2024

Annals of Gastroent Surgery

View full text Add to dashboard Cite

AimPancreatic reconstruction after pancreaticoduodenectomy (PD) that leaves a small remnant pancreas is often difficult. Pancreatic fistula is a major complication after PD, and fistulas are rare in patients with hard pancreas. However, the clinical impact of non‐reconstructed small remnant after PD with hard pancreas is unknown.MethodsWe included all patients who underwent PD for pancreatic tumor without pancreatic reconstruction in two institutions supervised by one surgeon between January 2004 and March 2021. Their short‐ or long‐term outcome after surgery was retrospectively analyzed.ResultsPD was performed in 774 patients, of whom 16 patients were without reconstruction (2.1%) with negative margins at the pancreatic stump. Pancreatic transection was performed above or to the left of the superior mesenteric artery, with a median remnant pancreas length of 3.7 cm (range, 1.3–10.0). A major complication (≥ Clavien–Dindo Grade IIIa) occurred in one patient (6%). Fistula of grade B occurred in one patient (6%). After a median follow‐up of 44 months (95%CI, 10.6–77.3), insulin administration was unnecessary in 11 patients.ConclusionThe preservation of a small pancreatic remnant without reconstruction after PD can be performed safely and may enable the keeping of pancreatic endocrine function for some selected patients with hard pancreas.

show abstract

Multimodal treatment combining neoadjuvant therapy, laparoscopic subtotal distal pancreatectomy and adjuvant therapy for pancreatic neck-body cancer: Case series

Li,

Wang,

Wang

et al. 2025

World J Gastrointest Surg

View full text Add to dashboard Cite

BACKGROUND Pancreatic cancer involving the pancreas neck and body often invades the retroperitoneal vessels, making its radical resection challenging. Multimodal treatment strategies, including neoadjuvant therapy, surgery, and postoperative adjuvant therapy, are contributing to a paradigm shift in the treatment of pancreatic cancer. This strategy is also promising in the treatment of pancreatic neck-body cancer. AIM To evaluate the feasibility and effectiveness of a multimodal strategy for the treatment of borderline/locally advanced pancreatic neck-body cancer. METHODS From January 2019 to December 2021, we reviewed the demographic characteristics, neoadjuvant and adjuvant treatment data, intraoperative and postoperative variables, and follow-up outcomes of patients who underwent multimodal treatment for pancreatic neck-body cancer in a prospectively collected database of our hospital. This investigation was reported in line with the Preferred Reporting of Case Series in Surgery criteria. RESULTS A total of 11 patients with pancreatic neck-body cancer were included in this study, of whom 6 patients were borderline resectable and 5 were locally advanced. Through multidisciplinary team discussion, all patients received neoadjuvant therapy, of whom 8 (73%) patients achieved a partial response and 3 patients maintained stable disease. After multidisciplinary team reassessment, all patients underwent laparoscopic subtotal distal pancreatectomy and portal vein reconstruction and achieved R0 resection. Postoperatively, two patients (18%) developed ascites, and two patients (18%) developed pancreatic fistulae. The median length of stay of the patients was 11 days (range: 10-15 days). All patients received postoperative adjuvant therapy. During the follow-up, three patients experienced tumor recurrence, with a median disease-free survival time of 13.3 months and a median overall survival time of 20.5 months. CONCLUSION A multimodal treatment strategy combining neoadjuvant therapy, laparoscopic subtotal distal pancreatectomy, and adjuvant therapy is safe and feasible in patients with pancreatic neck-body cancer.

show abstract

Proximal subtotal pancreatectomy as an alternative to total pancreatectomy for malnourished patients

Cited by 3 publications

References 24 publications

Clinical outcomes of organ‐preserving pancreatectomy for benign or low‐grade malignant pancreatic tumors: A multicenter nationwide survey in Japan

Clinical outcomes of organ‐preserving pancreatectomy for benign or low‐grade malignant pancreatic tumors: A multicenter nationwide survey in Japan

Low incidence of pancreatic fistula and well‐preserved endocrine function with non‐reconstructed small remnant pancreas after pancreaticoduodenectomy

Multimodal treatment combining neoadjuvant therapy, laparoscopic subtotal distal pancreatectomy and adjuvant therapy for pancreatic neck-body cancer: Case series

Contact Info

Product

Resources

About